TCRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer...

Stats
Today's Volume	108 835
Average Volume	209 604
Market Cap	337.07M
EPS	$0 ( 2024-05-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.73
ATR14	$0.0200 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Louis Chrystal	Buy	380 000	Stock Option (Right to Buy)
2024-04-22	Louis Chrystal	Buy	0
2024-04-19	Baker Bros. Advisors Lp	Buy	8 851 451	Warrants to purchase Common Stock
2024-04-19	Baker Bros. Advisors Lp	Buy	825 968	Warrants to purchase Common Stock
2024-04-19	Lynx1 Capital Management Lp	Buy	5 000 000	Pre-funded Warrant (right to buy)

INSIDER POWER
99.18
Last 92 transactions
Buy: 66 852 110 \| Sell: 5 443 695

Volume Correlation

Long: -0.29 (neutral)

Short: -0.94 (very strong negative)

Signal:(23.689) Possible Trading Opportunity Present (swing)

TScan Therapeutics, Inc. Correlation

10 Most Positive Correlations
CRTO	0.899
EBSB	0.886
VSEC	0.884
ADSE	0.882
COOP	0.882
QNST	0.88
TXRH	0.878
SKYW	0.876
AAON	0.876
EVER	0.875

10 Most Negative Correlations
LTRX	-0.906
HFFG	-0.889
ATNX	-0.881
SLVO	-0.879
BRQS	-0.878
TRIT	-0.875
CNTG	-0.873
CYAN	-0.872
CUE	-0.87
VORB	-0.867

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TScan Therapeutics, Inc. Correlation - Currency/Commodity

-0.45
( neutral )

-0.44
( neutral )

0.00
( neutral )

-0.62
( weak negative )

0.23
( neutral )

TScan Therapeutics, Inc. Financials

Annual	2023
Revenue:	$21.05M
Gross Profit:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2023
Revenue:	$21.05M
Gross Profit:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2022
Revenue:	$13.54M
Gross Profit:	$8.40M (62.05 %)
EPS:	$-2.74

FY	2021
Revenue:	$10.14M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-4.17

Financial Reports:

No articles found.

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.